Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
Abstract There are prevalent financial relationships between dermatologists and pharmaceutical companies in Japan. However, little was known about the extent of whole picture of the personal payments made to dermatologists by pharmaceutical companies. This study aimed to examine the personal payment...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-34705-8 |
| _version_ | 1797827504200744960 |
|---|---|
| author | Anju Murayama Sae Kamamoto Hiroaki Saito Akihiko Ozaki |
| author_facet | Anju Murayama Sae Kamamoto Hiroaki Saito Akihiko Ozaki |
| author_sort | Anju Murayama |
| collection | DOAJ |
| description | Abstract There are prevalent financial relationships between dermatologists and pharmaceutical companies in Japan. However, little was known about the extent of whole picture of the personal payments made to dermatologists by pharmaceutical companies. This study aimed to examine the personal payments to the board-certified dermatologists by the Japanese Dermatological Association from the pharmaceutical companies between 2016 and 2019. Using the publicly disclosed payments data by the pharmaceutical companies between 2016 and 2019, we evaluated the magnitude, prevalence, and trends in the personal payments made to all board-certified dermatologists for the lecturing, writing, and consulting compensations. The payments were descriptively analyzed overall and by dermatologist demographics. Additionally, the payment trends were assessed by generalized estimating equation models. Of 6883 active board-certified dermatologists, 3121 (45.3%) received a total of $33,223,806 personal payments between 2016 and 2019. The median per-physician payments and number of payments (interquartile range) were $1737 ($613–$5287) and 4.0 (2.0–10.0) over the 4 years, respectively. Only top 1%, 5%, 10% of dermatologists received 41.7% (95% confidence interval [CI] 38.2–45.1%), 76.9% (95% CI 74.7–79.1%), and 87.6% (95% CI 86.2–88.9%) of overall payments. The number of dermatologists receiving payments and per-dermatologist payments increased by 4.3% (95% CI 3.1‒5.5%, p < 0.001) and 16.4% (95% CI 13.5‒19.4%, p < 0.001) each year. The board-certification in dermatology-oncology, in cosmetic dermatology, and male sex were significantly associated with higher personal payments with relative monetary values of 2.29 (95% CI 1.65–3.19, p < 0.001), 3.16 (95% CI 1.89–5.26, p < 0.001), and 5.38 (95% CI 4.12–7.04, p < 0.001). Less than half of Japanese board-certified dermatologists received lower personal payments from the pharmaceutical companies than those to other specialists. However, these personal payments were increasingly more prevalent and greater over the 4 years. |
| first_indexed | 2024-04-09T12:49:22Z |
| format | Article |
| id | doaj.art-5af3362c04894ca29547c46fef1a8cbc |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T12:49:22Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-5af3362c04894ca29547c46fef1a8cbc2023-05-14T11:17:18ZengNature PortfolioScientific Reports2045-23222023-05-011311910.1038/s41598-023-34705-8Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019Anju Murayama0Sae Kamamoto1Hiroaki Saito2Akihiko Ozaki3Tohoku University School of MedicineFaculty of Medicine, Hamamatsu University School of MedicineMedical Governance Research InstituteFaculty of Medicine, Hamamatsu University School of MedicineAbstract There are prevalent financial relationships between dermatologists and pharmaceutical companies in Japan. However, little was known about the extent of whole picture of the personal payments made to dermatologists by pharmaceutical companies. This study aimed to examine the personal payments to the board-certified dermatologists by the Japanese Dermatological Association from the pharmaceutical companies between 2016 and 2019. Using the publicly disclosed payments data by the pharmaceutical companies between 2016 and 2019, we evaluated the magnitude, prevalence, and trends in the personal payments made to all board-certified dermatologists for the lecturing, writing, and consulting compensations. The payments were descriptively analyzed overall and by dermatologist demographics. Additionally, the payment trends were assessed by generalized estimating equation models. Of 6883 active board-certified dermatologists, 3121 (45.3%) received a total of $33,223,806 personal payments between 2016 and 2019. The median per-physician payments and number of payments (interquartile range) were $1737 ($613–$5287) and 4.0 (2.0–10.0) over the 4 years, respectively. Only top 1%, 5%, 10% of dermatologists received 41.7% (95% confidence interval [CI] 38.2–45.1%), 76.9% (95% CI 74.7–79.1%), and 87.6% (95% CI 86.2–88.9%) of overall payments. The number of dermatologists receiving payments and per-dermatologist payments increased by 4.3% (95% CI 3.1‒5.5%, p < 0.001) and 16.4% (95% CI 13.5‒19.4%, p < 0.001) each year. The board-certification in dermatology-oncology, in cosmetic dermatology, and male sex were significantly associated with higher personal payments with relative monetary values of 2.29 (95% CI 1.65–3.19, p < 0.001), 3.16 (95% CI 1.89–5.26, p < 0.001), and 5.38 (95% CI 4.12–7.04, p < 0.001). Less than half of Japanese board-certified dermatologists received lower personal payments from the pharmaceutical companies than those to other specialists. However, these personal payments were increasingly more prevalent and greater over the 4 years.https://doi.org/10.1038/s41598-023-34705-8 |
| spellingShingle | Anju Murayama Sae Kamamoto Hiroaki Saito Akihiko Ozaki Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 Scientific Reports |
| title | Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 |
| title_full | Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 |
| title_fullStr | Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 |
| title_full_unstemmed | Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 |
| title_short | Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 |
| title_sort | pharmaceutical payments to japanese board certified dermatologists a 4 year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 |
| url | https://doi.org/10.1038/s41598-023-34705-8 |
| work_keys_str_mv | AT anjumurayama pharmaceuticalpaymentstojapaneseboardcertifieddermatologistsa4yearretrospectiveanalysisofpersonalpaymentsfrompharmaceuticalcompaniesbetween2016and2019 AT saekamamoto pharmaceuticalpaymentstojapaneseboardcertifieddermatologistsa4yearretrospectiveanalysisofpersonalpaymentsfrompharmaceuticalcompaniesbetween2016and2019 AT hiroakisaito pharmaceuticalpaymentstojapaneseboardcertifieddermatologistsa4yearretrospectiveanalysisofpersonalpaymentsfrompharmaceuticalcompaniesbetween2016and2019 AT akihikoozaki pharmaceuticalpaymentstojapaneseboardcertifieddermatologistsa4yearretrospectiveanalysisofpersonalpaymentsfrompharmaceuticalcompaniesbetween2016and2019 |